Wire Stories
-
29.1KK-Pop Star Lee HongKi�s Music NFT Sold Out in About 1 Hour After Its Launch on Muverse!
SEOUL, South Korea–(BUSINESS WIRE)–South Korea’s popular singer Lee HongKi has released his new track and mint as music NFT on the Muverse...
-
31.4KChina Eastern livestream brings together Chinese and Italian university students at first day of Wenzhou-Rome direct flight
SHANGHAI–(BUSINESS WIRE)–On October 27 China Eastern Airlines (CEA) launched a direct flight between Whenzhou, China and Rome, Italy. From then on, the...
-
29.6KSino-German “Generation Z” Uncover In-flight Meals with CEA Chefs
SHANGHAI–(BUSINESS WIRE)–On October 28, teachers and students from Chinese and German universities participated in the livestream activity hosted by China Eastern Airlines...
-
26.7KTimberland Bancorp�s Fiscal Fourth Quarter Net Income Increases 23%
Quarterly EPS Increases 23% to $0.85 from $0.69 for the Preceding Quarter Quarterly Return on Average Assets Increases to 1.51% Quarterly Return...
-
28.0KBitcoin.com Officially Expands Access to DeFi with Public Sale of Ecosystem Utility Token VERSE
Whitelisted individuals for the sale will be able to purchase VERSE tokens using BTC, BCH, ETH and USDT/USDC. SAINT KITTS AND NEVIS,...
-
31.6KNew Vonage Study Reveals That Consumers Want Digital Interactions With Brands to Feel More Like Personal Conversations
Vonage 11th Annual Global Customer Engagement Report reveals technology gap prevents meaningful connections and risks loyalty among customers SINGAPORE–(BUSINESS WIRE)–Vonage, a global...
-
29.5KEucure Biopharma, a Subsidiary of Biocytogen, Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using YH003 Antibody Sequence
YH003 is an agonistic anti-CD40 IgG2 monoclonal antibody with best-in-class potential YH003 in combination with PD-1 are being dosed in phase II...
-
31.3KEucure Biopharma, a Subsidiary of Biocytogen, Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using YH003 Antibody Sequence
YH003 is an agonistic anti-CD40 IgG2 monoclonal antibody with best-in-class potential. YH003 in combination with PD-1 are being dosed in phase II...
-
34.7KAirwallex partners with University of Melbourne to forge Australia�s future tech leaders
MELBOURNE, Australia–(BUSINESS WIRE)–Global fintech Airwallex has embarked on a pivotal partnership with the University of Melbourne, which will help build the next...
-
29.8KOrum Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ORM-5029 in Development to Treat HER2-Expressing Advanced Solid Tumors
ORM-5029 is a first-in-class drug candidate designed to selectively deliver catalytic GSPT1 protein degraders to HER2-expressing tumor cells via antibody targeting BOSTON...
To Top